UNITED STATES |
|
||||||||||||||||||||||||||||||
SECURITIES AND EXCHANGE COMMISSION | |||||||||||||||||||||||||||||||
Washington, D.C. 20549 | |||||||||||||||||||||||||||||||
FORM 25 | |||||||||||||||||||||||||||||||
NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. | |||||||||||||||||||||||||||||||
Commission File Number | 001-35892 | ||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||
Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration: | |||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||
Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person. | |||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. |
Chat with this insight
Save time and jump to the most important pieces.
IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel
Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, Actelion Pharmaceuticals, Eisai, GSK, and the U.S. FDASOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that Douglas B. Snyder, joined the company as its Senior Vice President, General Counsel on September 18, 2024. "Doug brings a broad legal background in the healthcare field spanning biotechnology, pharm
Jazz Pharmaceuticals Completes Acquisition of GW Pharmaceuticals plc
DUBLIN, May 5, 2021 /PRNewswire/ -- Jazz Pharmaceuticals (NASDAQ:JAZZ) today announced the completion of its acquisition of GW Pharmaceuticals plc (NASDAQ:GWPH) ("GW"), a leader in the science, development and commercialization of cannabinoid-based prescription medicines. "We are excited to welcome our GW colleagues to Jazz as we mark a transformative milestone in creating an innovative, high-growth, global biopharma leader in neuroscience with a worldwide commercial and operational footprint," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals. "The addition of GW further diversifies our commerical portfolio and innovative pipeline with therapies that are compl
GW Pharmaceuticals recognised for leadership in prescription cannabis-based medicines with prestigious Queen's Award for Enterprise in Innovation
LONDON, April 29, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH) ("GW", "the Company" or "the Group"), a world leader in discovering, developing and commercialising regulatory approved cannabis-based medicines, announces that it has received the Queen's Award for Enterprise 2021 in the Innovation category, recognising GW's innovative and ground-breaking work to harness cannabinoid science to create the world's first regulatory approved, prescription cannabis-based medicines. Since its inception in 1998, GW has successfully navigated significant barriers to enable the development, manufacture and commercialisation of regulatory approved cannabis-based medicines, leading the
Raymond James resumed coverage on GW Pharmaceuticals
Raymond James resumed coverage of GW Pharmaceuticals with a rating of Hold
GW Pharmaceuticals downgraded by Citigroup
Citigroup downgraded GW Pharmaceuticals from Buy to Neutral
GW Pharmaceuticals downgraded by HC Wainwright
HC Wainwright downgraded GW Pharmaceuticals from Buy to Neutral
SEC Form 4: Tovey Christopher J. returned 2,496 units of Ordinary Shares to the company, decreasing direct ownership by 100% to 0 units
4 - GW PHARMACEUTICALS PLC (0001351288) (Issuer)
SEC Form 4: Cline Darren S returned 5,556 units of Ordinary Shares to the company, decreasing direct ownership by 100% to 0 units
4 - GW PHARMACEUTICALS PLC (0001351288) (Issuer)
SEC Form 4 filed by GRYSKA DAVID W
4 - GW PHARMACEUTICALS PLC (0001351288) (Issuer)
SEC Form 15-12B filed by GW Pharmaceuticals Plc
15-12B - GW PHARMACEUTICALS PLC (0001351288) (Filer)
SEC Form S-8 POS filed by GW Pharmaceuticals Plc
S-8 POS - GW PHARMACEUTICALS PLC (0001351288) (Filer)
SEC Form S-8 POS filed by GW Pharmaceuticals Plc
S-8 POS - GW PHARMACEUTICALS PLC (0001351288) (Filer)
IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel
Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, Actelion Pharmaceuticals, Eisai, GSK, and the U.S. FDASOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that Douglas B. Snyder, joined the company as its Senior Vice President, General Counsel on September 18, 2024. "Doug brings a broad legal background in the healthcare field spanning biotechnology, pharm
How An Ancient Medicine Is Taking On The $16 Trillion Pharmaceutical Industry
LONDON, Dec. 3, 2020 /PRNewswire/ -- 2021 could be a big year for this soon-to-be $16-trillion biotech opportunity. More importantly, it could be a big year for companies pioneering a new form of therapy that could effectively treat the world's #1 disability. It's a disability that's costing the economy $1 trillion in lost production every single year. In fact, the revolutionary treatment could be at our doorstep by 2021. And the next few months are critical. Mentioned in today's commentary includes: Constellation Brands, Inc. (NYSE: STZ), Molson Coors Beverage Company (NYSE: TAP), Altria Group, Inc. (NYSE: MO), GW Pharmaceuticals plc (NASDAQ: GWPH), Curaleaf Holdings, Inc. (OTCQX: CUR
SEC Form SC 13G/A filed
SC 13G/A - GW PHARMACEUTICALS PLC (0001351288) (Subject)
SEC Form SC 13G/A filed
SC 13G/A - GW PHARMACEUTICALS PLC (0001351288) (Subject)
SEC Form SC 13G filed
SC 13G - GW PHARMACEUTICALS PLC (0001351288) (Subject)